Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio, Inc. (NYSE: IBIO) announced its participation in the Antibody Engineering & Therapeutics Conference 2022 in San Diego, presenting two posters highlighting applications of its AI-driven RubrYc Discovery Engine.
The presentations include AI-Designed Structural Immunogens targeting PD-1 Agonist and EGFRvIII tumor-specific epitopes. Additionally, they will showcase identification efforts of a potent PD-1 Agonist antibody and a targeted approach for tumor cells. The RubrYc Discovery Engine aims to develop effective immunotherapies for challenging cancers.
iBio, Inc. (NYSEA:IBIO) announces the immediate resignation of CEO Thomas F. Isett from both the Board of Directors and his executive duties. The current Chair, William (Chip) Clark, will oversee the leadership team during the search for a new CEO. Isett's contributions included enhancing iBio's portfolio and acquiring RubrYc’s drug discovery engine. The company emphasizes its commitment to developing innovative antibody treatments and maintaining its operations amidst leadership changes.
iBio, Inc. (NYSEA:IBIO) is divesting its contract development and manufacturing organization (CDMO) to focus on immuno-oncology assets and AI-driven drug discovery. This restructuring is expected to yield approximately 50% in annualized cost savings, reducing monthly expenses by $2.5-3.0 million. The divestiture process is aimed at advancing lead candidates like IBIO-101 and optimizing their proprietary technology, with expectations to complete the sale in 2023, contributing to a cash runway into mid-2024.
iBio has provided its preliminary unaudited financial results for the fiscal year ending June 30, 2022, reporting revenues of approximately $2.4 million, a slight increase of 1% from fiscal 2021. The company recorded a net loss of $50.3 million, expanding by $27.1 million due to rising R&D and administrative expenses. In a strategic move, iBio acquired assets from RubrYc Therapeutics, enhancing its immunotherapy portfolio. However, it has opted not to proceed with the IND submission for its COVID-19 vaccine candidate IBIO-202.
iBio announced the acquisition of RubrYc Therapeutics to enhance its immuno-oncology pipeline and AI-driven drug discovery capabilities. The acquisition includes a patented AI Drug Discovery Platform and rights to two previously licensed drug candidates, with an upfront payment of $1 million in stock. Potential development milestones of up to $5 million are also available. iBio aims to extend its cash runway and will discuss its strategic transformation and FY2022 results in a conference call on September 27, 2022.
iBio, Inc. announced successful completion of its first batch of a proprietary nucleocapsid antigen for the vaccine candidate IBIO-202 under cGMP conditions. This new vaccine aims to provide long-lasting protection against COVID-19 variants through the nucleocapsid protein, rather than the spike protein used in current vaccines. The company is analyzing data from its challenge studies to further validate this approach. iBio is actively pursuing funding opportunities with Congress to support next-generation COVID-19 vaccine development.
iBio, Inc. (NYSEA:IBIO) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company is known for its innovative FastPharming® Manufacturing System for biopharmaceuticals. A pre-recorded presentation will be available on demand for registered attendees starting May 24, 2022, and can also be accessed on iBio's website under 'News & Events'. iBio focuses on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases, leveraging its state-of-the-art manufacturing capabilities.
iBio, Inc. (NYSEA:IBIO) reported significant growth in revenue for Q3 FY2022, totaling approximately $1.9 million, up 154% from the previous year. The company is progressing towards clinical-stage status, with plans for its COVID-19 vaccine and the IL-2-sparing anti-CD25 antibody IBIO-101. Despite an increase in R&D and G&A expenses, leading to a net loss of $12.4 million, iBio maintains adequate cash reserves of approximately $48.6 million to support operations until September 2023. A special meeting for shareholders to approve a reverse stock split is forthcoming.
iBio, Inc. presented preclinical data on its monoclonal antibody candidate, IBIO-101, at the Frontiers in Cancer Immunotherapy 2022 conference. The research showed that IBIO-101, utilizing iBio's FastPharming and Glycaneering technologies, matched the efficacy of a traditional anti-CD25 antibody while enhancing effector function. The company plans to advance this anti-CD25 monoclonal antibody into clinical trials next year.
iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2022 third quarter financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing a detailed corporate update. The company specializes in next-generation biopharmaceuticals and sustainable, plant-based manufacturing through its FastPharming System. It focuses on developing treatments for cancers, fibrotic, and infectious diseases, along with offering contract development and manufacturing services.